Compare RBBN & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBBN | MYGN |
|---|---|---|
| Founded | 1997 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.4M | 444.2M |
| IPO Year | 2017 | 1996 |
| Metric | RBBN | MYGN |
|---|---|---|
| Price | $2.66 | $4.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $4.67 | ★ $7.64 |
| AVG Volume (30 Days) | ★ 974.9K | 967.5K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.97 | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $1.97 | $6.86 |
| Revenue Next Year | $6.69 | $5.45 |
| P/E Ratio | $12.66 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $1.83 | $3.76 |
| 52 Week High | $4.29 | $8.59 |
| Indicator | RBBN | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.72 | 49.69 |
| Support Level | $2.05 | $4.25 |
| Resistance Level | $2.88 | $5.52 |
| Average True Range (ATR) | 0.16 | 0.31 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 49.06 | 48.10 |
Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.